<DOC>
	<DOC>NCT02706873</DOC>
	<brief_summary>This is a randomized, double-blind study comparing ABT-494 monotherapy to Methotrexate (MTX) monotherapy in MTX-naïve subjects with moderately to severely active rheumatoid arthritis</brief_summary>
	<brief_title>A Study to Compare ABT-494 Monotherapy to Methotrexate Monotherapy in Subjects With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Duration of symptoms consistent with RA for ≥ 6 weeks who also fulfill the 2010 ACR/EULAR classification criteria for RA. Naïve to Methotrexate (MTX) or, if already on MTX, have received no more than 3 weekly MTX doses with requirement to complete a 4week MTX washout before the first dose of study drug. Subjects with prior exposure to conventional synthetic diseasemodifying antirheumatic drugs(csDMARDs) other than MTX may be enrolled if completed the washout period. Subject meets the following minimum disease activity criteria: greater than or equal to 6 swollen joints (based on 66 joint counts) and greater than or equal to 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits. greater than or equal to 1 bone erosion on xray (by local reading) OR in the absence of documented bone erosion, both positive rheumatoid factor and positive anticyclic citrullinated peptide autoantibodies are required at Screening. Intolerant to Methotrexate (MTX). Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to tofacitinib, baricitinib, and filgotinib). Prior exposure to any biologic diseasemodifying antirheumatic drugs (bDMARDs). History of any arthritis with onset prior to age 17 years or current diagnosis, inflammatory joint disease other than RA (including but not limited to gout, systemic lupus erythematosus, psoriatic arthritis, axial spondyloarthritis including ankylosing spondylitis and nonradiographic axial SpA, reactive arthritis, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, fibromyalgia [currently with active symptoms]. Current diagnosis of secondary Sjogren's Syndrome is permitted.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Musculoskeletal disease</keyword>
	<keyword>Anti-inflammatory agents</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Joint disease</keyword>
	<keyword>Antirheumatic agents</keyword>
</DOC>